A Novel Access to Arylated and Heteroarylated Beta-Carboline Based PDE5 Inhibitors

Nermin      S. Ahmed; Bernard      D. Gary; Gary      A. Piazza; Heather      N. Tinsley; Stefan      Laufer; Ashraf      H. Abadi

doi:10.2174/157340610793563992

Abstract

Starting from a previously reported lead compound GR30040X (a hydantoin tetrahydro-β-carboline derivative with a 4- pyridinyl ring at C- 5), a series of structurally related tetrahydro-β-carboline derivatives were prepared. The tetrahydro- β-carboline skeleton was fused either to a hydantoin or to a piperazindione ring, the pendant aryl group attached to C-5 or C-6 was changed to a 3, 4-dimethoxyphenyl or a 3-pyridinyl ring; different N-substituents on the terminal ring were introduced, a straight chain ethyl group, a branched tert. butyl and P-chlorophenyl group rather than n-butyl group of the lead compound. All four possible diastereomers of target tetrahydro-β-carboline derivatives were prepared, separated by column chromatography and the significance of these stereochemical manipulations was studied. Synthesized compounds were evaluated for their inhibitory effect versus PDE5. Seven hits were obtained with appreciable inhibitory activity versus PDE5 with IC50s 0.14 - 4.99 μM.

Keywords: 3- pyridine, cGMP, MED, PDE5, tadalafil, tetrahydro-β-carboline, PDEs, chronic obstructive pulmonary disease, column chromatography, C-NMR spectroscopy, THBCs-hydantoin skeleton, Nicolet Avatar 380 spectrometer